Yue Kong

Yue Kong

Auto-generated profile, based on publicly available information

Yue Kong

Center for Reproductive Medicine The First Affiliated Hospital of Zhengzhou University Zhengzhou China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

22 June 2024 in Cancer Letters
Verified
Journal Article
Closed access
XFXu Feng
Xu Feng
ZJZhaodong Ji
Zhaodong Ji
XFXiaoxi Fan
Xiaoxi Fan
YKYue Kong
Yue Kong
YYYinjue Yu
Yinjue Yu
GYGong Yang
Gong Yang

18 September 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
YKYue Kong
Yue Kong
GYGuang Yang
Guang Yang
XFXu Feng
Xu Feng
ZJZhaodong Ji
Zhaodong Ji
XWXiaoling Wang
Xiaoling Wang
GYGong Yang
Gong Yang
Some patients with polycystic ovarian syndrome (PCOS) suffered from metabolic syndrome (MetS) including dyslipidemia, hyperinsulinism, but the underlying mechanism is unclear. Although C-terminal Binding Protein 1 (CTBP1) is a transcriptional co-repressor frequently involved in hormone secretion disorders and MetS-associated diseases, the role of CTBP1 in PCOS is rarely reported. In the present study, we found that CTBP1 expression was significantly elevated in primary granulosa cells (pGCs) derived from the PCOS with MetS patients and was positively associated with serum triglyceride, but negatively correlated with serum estradiol (E2) or high-density lipoprotein. Mechanistic study suggested that CTBP1 physically bound to the promoter II of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) to inhibit the aromatase gene transcription and expression, resulting in the reduced E2 synthesis. Moreover, CTBP1 interacted with the phosphorylated SREBP1a at S396 in nuclei, leading to the FBXW7-dependent protein degradation, resulting in the reduced lipid droplets formation in pGCs. Therefore, we conclude that CTBP1 in GCs dysregulates the synthesis of steroid hormones and lipids through suppression of aromatase expression and promotion of SREBP1a protein degradation in PCOS patients, which may offer some fresh insights into the potential pathological mechanism for this tough disease.